Opinion|Videos|January 10, 2025
Understanding the CAR-T Treatment Process
Panelists discuss which patients are considered for CAR-T therapy in second-line treatment for relapsed/refractory multiple myeloma (R/R MM) (cilta-cel vs ide-cel), describe the specific criteria and institutional guidelines used to determine patient eligibility, and explore how non-medical factors like such as location and financial considerations impact patient selection, while also outlining the typical CAR-T referral process from community physician outreach to patient evaluation and selection.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Which patients do you think about consider for CAR-T in second-line treatment for R/R MM (cilta-cel vs ide-cel)?
- Can you describe the specific criteria/institutional guidelines used to determine patient eligibility for CAR-T referral?
- How do non-medical factors (location, money, etc) impact patient selection?
- Walk us through the typical CAR-T referral process at your institution, - from the initial community physician outreach to the patient evaluation and selection.
Advertisement
Related to this article
Ralph V. Boccia, MD, FACP, discussed educating hospital teams and using tocilizumab to manage bispecific toxicities when patients need admission.
Ralph V. Boccia, MD, FACP, noted how designated hospitals and a 24/7 on-call team support emergencies during bispecific step-up dosing.
Ralph V. Boccia, MD, FACP, explained the caregiver’s role in monitoring and reporting during bispecific antibody step-up dosing.
Ralph V. Boccia, MD, FACP, explained who needs REMS certification and which care team members need training to deliver bispecific antibodies.
Saad Z. Usmani, MD, MBA, FACP, FASCO, discussed quadruplet induction, extended maintenance, and when a community clinician should call a myeloma center.
Saad Z. Usmani, MD, MBA, FACP, FASCO, discussed the threshold he will act on in standard-risk disease, and the trial that would make the decision firmer.
In a retrospective analysis, teclistamab produced response rates numerically higher than in MajesTEC-1, with missed doses not compromising outcomes.
Data from the phase 3 OCEAN trial and others support the expanded approval for melflufen in patients with previously treated multiple myeloma.
Advertisement
Advertisement
Trending on CancerNetwork
1
Subsequent Therapy May Have Narrowed the Overall Survival Gap in LITESPARK-011
2
FDA Approves Perioperative Durvalumab/Enfortumab Vedotin in MIBC
3
Managing Emergencies During Outpatient Bispecific Step-Up Dosing
4
ACS Updates Prostate Cancer Screening Guideline With Risk-Based PSA Intervals
5